|

Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65

RECRUITINGSponsored by Michael Moront
Actively Recruiting
SponsorMichael Moront
Started2025-01-01
Est. completion2026-07-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06917586

Summary

The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital
* Under the age of 65

Exclusion Criteria:

* Over the age of 65
* Under the age of 18
* Surgery performed at institutions outside of ProMedica Toledo Hospital

Conditions5

Heart DiseaseValve Disease, HeartValve Heart StenosisValve Regurgitation, MitralValve Replacement

Locations1 site

ProMedica Toledo Hospital
Toledo, Ohio, 43606
Dawn Muskiewicz, MS419-291-7517dawn.muskiewicz@promedica.org

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.